Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1015P - A phase I dose-escalation study of HBM4003: An anti-CTLA-4 heavy-chain-only mAb

Date

16 Sep 2021

Session

ePoster Display

Presenters

Paul de Souza

Citation

Annals of Oncology (2021) 32 (suppl_5): S829-S866. 10.1016/annonc/annonc705

Authors

P. de Souza1, J. Park2, D. Day3, S. Frentzas4, A.M. Haydon5, J. Ji6, M.M. de Assis7, X. Chen7, X. Gan7, X. Tao7, R. Zuo8, G. Ross9, L. Lu7

Author affiliations

  • 1 Medical Oncology, Western Sydney University - School of Medicine, 2560 - Campbelltown/AU
  • 2 Department Of Clinical Medicine, Macquarie University, Macquarie Park/AU
  • 3 Medical Oncology, Monash Health - Monash Cancer Centre, 3168 - Clayton/AU
  • 4 Medical Oncology Department, Monash Health - Monash Cancer Centre, 3165 - Bentleigh East/AU
  • 5 Medical Oncology, Alfred Hospital, 3004 - Melbourne/AU
  • 6 Medicine, Harbour BioMed Beijing Co Ltd, Beijing/CN
  • 7 Medicine, Harbour BioMed Shanghai Co Ltd, Shanghai/CN
  • 8 Medicine, Harbour BioMed Shanghai Co Ltd, 200032 - shanghai/CN
  • 9 Management Dept, Graham Ross Consulting Services, AL8 7PA - Welwyn Garden City/GB
More

Abstract 1015P

Background

HBM4003 is a fully heavy-chain-only monoclonal antibody (mAb) to CTLA-4, which was engineered to deplete Treg cells by enhanced ADCC.

Methods

This is a first-in-human, phase I study to evaluate the safety, anti-tumor activity, PK/PD and recommended phase II dose of HBM4003. In part 1 (presented here), patients (pts) were enrolled into 3 dose levels (DL): 0.3mg/kg QW (28-day cycle), 0.45mg/kg Q3W (21-day cycle), and 0.6mg/kg Q3W (21-day cycle). Part 2 is a dose-expansion study.

Results

The study is ongoing. Twenty pts with advanced solid tumors have been treated at 4 Australian sites; 13 pts received ≥ 2 lines of systemic therapies and 8 received previous PD-1/PD-L1 mAb. The most common treatment-related AE (TRAE) of all grades was diarrhea (8[40%] pts), followed by colitis (5[25%] pts). Grade (Gr) 3 TRAEs are shown in the table. Table: 1015P

Grade (Gr) 3 TRAEs

DL N, Enrolled (n, evaluable) Gr 3 TRAE n, % Gr 3 Diarrhea * n, %
0.3mg/kg QW 7 (6) diarrhea, 2, 28.6% diarrhea, 2, 28.6%
0.45mg/kg Q3W 7 (6) increased blood bilirubin and LFT increased**,1, 14.3% 0
0.6mg/kg Q3W 6 (6) diarrhea, 4, 66.7% diarrhea, 4, 66.7%

*No associated colitis or typical pathological changes, resolved with standard steroid treatment **Total bilirubin increased from normal to Gr 3, and LFT increased from Gr 1 to Gr 3. Other TRAEs included pruritus (3 [15%] pts), rash (4 [20%] pts), and hyperhidrosis (1 [5%] pt); all were Gr 1 or 2. There was 1 DLT (0.3mg/kg QW) with Gr 2 colitis and Gr 3 diarrhea. TRAE leading to discontinuation occurred in 8 pts. No DLT was observed in the Q3W DL. No Gr 4 or Gr 5 TRAE was reported. Fourteen pts were evaluable for efficacy: 9 had SD as best response, whereas 1 pt had confirmed PR as best response [0.45mg/kg Q3W, HCC, pre-treated with sorafenib, lenvatinib, and anti-PD-1, with tumor shrinkage of 22.2% (Week 6), 48.9% (Week 12), 53.3% (Week 16), and 64.4% (Week 24); AFP also declined from 170 u/l to <10u/l at Week 24], and 1pt (0.3mg/kg QW, CRPC) had SD with a PSA response. HBM4003 demonstrated near dose-proportional PK and extended PD effect. Immunogenicity was low.

Conclusions

Preliminary results for HBM4003 are encouraging. At 0.45mg/kg Q3W, there was no DLT and no cases of grade 3 diarrhea. There was one confirmed PR. Hence 0.45mg/kg Q3W was selected as the RP2D for part 2.

Clinical trial identification

NCT04135261.

Editorial acknowledgement

Legal entity responsible for the study

Harbour BioMed US, Inc.

Funding

Harbour BioMed US, Inc.

Disclosure

J. Ji: Financial Interests, Institutional, Full or part-time Employment: HBM Holdings Limited. M.M. de Assis: Financial Interests, Institutional, Full or part-time Employment: HBM Holdings Limited. X. Chen: Financial Interests, Institutional, Full or part-time Employment: HBM Holdings Limited. X. Gan: Financial Interests, Institutional, Full or part-time Employment: HBM Holdings Limited. X. Tao: Financial Interests, Institutional, Full or part-time Employment: HBM Holdings Limited. R. Zuo: Financial Interests, Institutional, Full or part-time Employment: HBM Holdings Limited. G. Ross: Financial Interests, Personal, Full or part-time Employment, Director: Graham Ross Oncology Consulting Services Ltd; Financial Interests, Personal, Stocks/Shares, Former Employee: Roche; Financial Interests, Personal, Stocks/Shares, Wife - Spouse: Roche; Financial Interests, Personal, Stocks/Shares, Former Employee: AstraZeneca; Financial Interests, Institutional, Other, Consultant: HBM Holdings Limited. L. Lu: Financial Interests, Institutional, Full or part-time Employment: HBM Holdings Limited. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.